MeiraGTx Shares Rise on Positive Data for Parkinson's Disease Treatment

Dow Jones10-15

By Don Nico Forbes

Shares in MeiraGTx rose after the company said it received positive data in a clinical bridging study of AAV-GAD for the treatment of Parkinson's disease.

Shares were up nearly 14% in premarket trading at $4.64, but remain down 34% year to date.

The biotechnology company said the study showed clinically meaningful improvements in key areas at 26 weeks, with the treatment well tolerated by patients and no serious adverse events.

Chief Executive Alexandria Forbes said the results underpin discussions with regulators in the U.S., Europe, and Japan, with the goal of initiating a Phase 3 study for AAV-GAD.

Write to Don Nico Forbes at don.forbes@wsj.com

(END) Dow Jones Newswires

October 15, 2024 08:15 ET (12:15 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475059135?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-15 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475059135","market":"nz","top_or_hot":-1,"title":"MeiraGTx Shares Rise on Positive Data for Parkinson's Disease Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Don Nico Forbes \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares in MeiraGTx rose after the company said it received positive data in a clinical bridging study of AAV-GAD for the treatment of Parkinson's disease. \n</p>\n<p>\n  Shares were up nearly 14% in premarket trading at $4.64, but remain down 34% year to date. \n</p>\n<p>\n  The biotechnology company said the study showed clinically meaningful improvements in key areas at 26 weeks, with the treatment well tolerated by patients and no serious adverse events. \n</p>\n<p>\n  Chief Executive Alexandria Forbes said the results underpin discussions with regulators in the U.S., Europe, and Japan, with the goal of initiating a Phase 3 study for AAV-GAD. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Don Nico Forbes at don.forbes@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 15, 2024 08:15 ET (12:15 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MeiraGTx Shares Rise on Positive Data for Parkinson's Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeiraGTx Shares Rise on Positive Data for Parkinson's Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-15 20:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Don Nico Forbes \n\n\n \n\n\n  Shares in MeiraGTx rose after the company said it received positive data in a clinical bridging study of AAV-GAD for the treatment of Parkinson's disease. \n\n\n  Shares were ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MGTX","symbol_name":"Meiragtx Holdings Plc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2475059135","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475059135","pubTimestamp":1728994500,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares in MeiraGTx rose after the company said it received positive data in a clinical bridging study of AAV-GAD for the treatment of Parkinson's disease.Shares were up nearly 14% in premarket trading at $4.64, but remain down 34% year to date.The biotechnology company said the study showed clinically meaningful improvements in key areas at 26 weeks, with the treatment well tolerated by patients and no serious adverse events.Chief Executive Alexandria Forbes said the results underpin discussions with regulators in the U.S., Europe, and Japan, with the goal of initiating a Phase 3 study for AAV-GAD.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MGTX":"Meiragtx Holdings Plc","BK4139":"生物科技"},"translate_title":"MeiraGTx股价因帕金森病治疗的积极数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGTX":0.9},"content_text":"By Don Nico Forbes \n\n\n \n\n\n  Shares in MeiraGTx rose after the company said it received positive data in a clinical bridging study of AAV-GAD for the treatment of Parkinson's disease. \n\n\n  Shares were up nearly 14% in premarket trading at $4.64, but remain down 34% year to date. \n\n\n  The biotechnology company said the study showed clinically meaningful improvements in key areas at 26 weeks, with the treatment well tolerated by patients and no serious adverse events. \n\n\n  Chief Executive Alexandria Forbes said the results underpin discussions with regulators in the U.S., Europe, and Japan, with the goal of initiating a Phase 3 study for AAV-GAD. \n\n\n \n\n\n  Write to Don Nico Forbes at don.forbes@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 15, 2024 08:15 ET (12:15 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475059135"}